title: Targeting the PI3-kinase/Akt/mTOR signaling pathway.
abstract: This article presents an overview of the PI3K/Akt/mTOR signaling pathway. As a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types. Biochemical and genetic aberrations of this pathway observed in various cancer types are explored. Last, pathway inhibitors both in development and already approved by the Food and Drug Administration are discussed.
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Unit 0107, Houston, TX 77030, USA.
authors.forename: Burhan
authors.initials: B
authors.lastname: Hassan
authors.forename: Argun
authors.initials: A
authors.lastname: Akcakanat
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Holder
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases
keywords: Cell signaling; Molecular targeted therapy; PI3K/Akt/mTOR signaling pathway; PTEN